Research Progress in Treatment of HR-Positive/HER 2-Low Advanced Breast Cancer: Interpretation of Breast Cancer Research Hotspots in 2024 ASCO
10.3971/j.issn.1000-8578.2025.24.1033
- VernacularTitle:HR阳性HER2低表达晚期乳腺癌治疗研究进展：2024 ASCO会议乳腺癌研究热点解读
- Author:
Yiwen MA
1
;
Junnan XU
1
;
Tao SUN
1
Author Information
1. Department of Oncology, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, China.
- Publication Type:SPECIALFEATURE
- Keywords:
HR-positive;
HER2-low expression;
CDK4/6 inhibitors;
T-DXd;
Breast cancer
- From:
Cancer Research on Prevention and Treatment
2025;52(2):98-102
- CountryChina
- Language:Chinese
-
Abstract:
HR-positive HER2-low breast cancer is a new hotspot therapeutic subtype, accounting for approximately 53.7% of all breast cancers. Patients with this type of cancer tend to have a high rate of lymph node metastasis and poor sensitivity to neoadjuvant chemotherapy and conventional anti-HER2 therapy, and exploring therapeutic strategies for this subtype of patient is a current clinical challenge. Therapeutic strategies for HR-positive HER2-low breast cancer are constantly being updated, including CDK4/6 inhibitors across the lines of therapy, and next-generation antibody-drug conjugates such as T-DXd. With the accumulation of high-level evidence-based evidence for HR-positive HER2-low breast cancer in the future, the research data will provide more practical support for precise diagnosis and treatment, thereby improving the prognosis of patients with HR-positive HER2-low breast cancer.
